REPORT SCOPE
INTRODUCTION
STUDY GOALS AND OBJECTIVES
The aim of this report is to provide a range of information, from detailed market analyses through industry trends, to quantify and qualify the emerging market for monoclonal and polyclonal antibody drugs. Forecasts and trends are gleaned from interviews with industry sources as well as from considered assessment of available and emerging technologies. The report develops forecasts for the pharmaceutical antibodies market for major disease applications from 1998 through 2004 and examines strategies employed by biotechnology companies and pharmaceuticals firms to develop and market products in this explosive market sector.
CONTRIBUTIONS OF THE STUDY AND FOR WHOM
Antibody-based drugs, in particular monoclonal antibody-based products, are on the brink of significant commercial growth. New developments are spurred in part by advances in technology that have now surmounted previous technical barriers to commercialization. The information and analyses presented in this report on antibody-based drugs is an important asset in decision-making for managers involved in development, marketing, market research, product development, mergers and acquisitions, licensing, management, investment banking and deal creation, and to consultants to the pharmaceutical and biotechnology industry. The study provides a comprehensive analysis of the current markets for antibody drugs and, in particular, the market potential of promising drugs and technologies under development.
METHODOLOGY
The base year for this study is 1999. Figures are based on revenue figures at the manufacturers' level and are projected at 1999 dollar value; inflation is not computed into the projection figures.
Information to prepare this study was derived from interviews with product managers, marketing strategists, research executives, and others at leading pharmaceutical and biotechnology companies that compete in the market for antibody drugs or which have products in development for this market.
SCOPE AND FORMAT
This report analyzes and assesses therapeutic and in vivo diagnostic imaging applications of antibodies in human medicine. Polyclonal and monoclonal antibodies are both included in this report, which is intended to be comprehensive with respect to products as well as applications.
Therapeutic and diagnostic imaging antibodies for veterinary use are excluded from this report. Also excluded are in vitro immunoassay applications of antibodies.
The scope of the study is worldwide. The Overview section provides a description of major technical issues involved in the development of antibody drugs, new directions in antibody research, valuation of antibody product sales, major issues, and differences in applicability of monoclonal and polyclonal antibody products.
The section on Technology describes antibody classes and types of products.
The Products section provides a synopsis of more than 170 polyclonal and monoclonal antibody drugs and diagnostics, including those currently marketed and those in development. Comparative product and sales analyses are provided for individual products. Tables include current and forecasted sales by individual product, as well as worldwide market size and growth estimates for the polyclonal and monoclonal therapeutic and diagnostic categories as a whole.
Therapeutic and Diagnostic Applications provides an overview of the leading indications for available and emerging antibody-based therapeutics and diagnostics, including selected indications for cancer, cardiovascular diseases, infectious diseases, organ transplant rejection, bone marrow transplants/graft-versus-host disease, rheumatoid arthritis, Crohn's disease, Rh isoimmunity, and psoriasis.
The section on Industry Structure provides an overview of the structure of the antibody industry, as well as a discussion of the pending huge impact of genomics and of the emergence of biotech firms into the market mainstream.
The section on Company Profiles emphasizes companies that lead the pharmaceutical and biotechnology industry in the research and development of antibody drugs and the innovative products they have launched or have in development.
INFORMATION SOURCES
The information and analyses presented in this report are based on an extensive survey of the biotechnology and pharmaceutical industries as well as a detailed examination of published literature and reports obtained from regulatory authorities, medical research institutions, pharmaceutical trade associations, and national and world health organizations. Key information from the literature was used as a basis to conduct dialogue and obtain expert opinion on commercial potential and market sizes from industry professionals.
Source: BCC, Inc.
